Sökning: onr:"swepub:oai:DiVA.org:liu-133889" >
Primary Gonadal Ins...
Primary Gonadal Insufficiency in Male and Female Childhood Cancer Survivors in a Long-Term Follow-Up Clinic
-
- Gunn, Harriet M. (författare)
- Childrens Hospital Westmead, Australia; University of Sydney, Australia
-
- Rinne, Ida (författare)
- Linköpings universitet,Medicinska fakulteten
-
- Emilsson, Hanna (författare)
- Linköpings universitet,Medicinska fakulteten
-
visa fler...
-
- Gabriel, Melissa (författare)
- Childrens Hospital Westmead, Australia
-
- Maguire, Ann M. (författare)
- University of Sydney, Australia; Childrens Hospital Westmead, Australia
-
- Steinbeck, Katharine S. (författare)
- Childrens Hospital Westmead, Australia; University of Sydney, Australia
-
visa färre...
-
(creator_code:org_t)
- MARY ANN LIEBERT, INC, 2016
- 2016
- Engelska.
-
Ingår i: Journal of Adolescent and Young Adult Oncology. - : MARY ANN LIEBERT, INC. - 2156-5333 .- 2156-535X. ; 5:4, s. 344-350
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Purpose: Childhood cancer survivors (CCS) are at increased risk of primary gonadal insufficiency (PGI). This study evaluated the prevalence and clinical characteristics of PGI in CCS. Methods: In this single-center, retrospective, observational, longitudinal study, we characterized CCS with PGI attending the oncology Long-Term Follow-Up (LTFU) Clinic at an Australian university hospital (January 2012-August 2014). From a cohort of 276 CCS, 54 (32 males) met criteria for PGI: elevated gonadotropins plus low estradiol/amenorrhoea (females) or low testosterone/small testicles for age (males). Results: Median age at primary diagnosis was 4.8 years (inter-quartile range [IQR] 3.0-9.7 years) and at LTFU, it was 22.3 years (IQR 18.2-25.7 years). Fifty-three participants (98.1%) were treated with known highly gonadotoxic therapies: alkylating chemotherapy (96.3%), radiotherapy (70.3%), total body irradiation (29.6%), bone marrow transplantation (51.9%), or multimodal protocols (68.5%). At primary diagnosis, 86.7% participants were Tanner stage I and at LTFU, 89.1% participants were Tanner stage V. More females (95.5%; n=21) than males (40.6%; n=13) were treated with hormone development therapy (HDT) (pamp;lt;0.01). Of these, more than half (n=18; 7 males) required pubertal induction. There was no significant difference in serum luteinizing hormone/follicle stimulating hormone (LH/FSH), testosterone/estradiol between those untreated and those treated with HDT. Among those on HDT, 60.7% had persistently elevated FSHLH and 33.3% had low testosterone or estradiol. Six males had semen analysis (five azoospermic, one oligospermic). Psychological assessment was documented in 61.1% of participants, and two-thirds reported fertility concerns. Conclusion: PGI is an evolving phenotype that is common in CCS. Suboptimal treatment and non-adherence occur frequently. Ongoing assessment is essential to ensure prompt diagnosis, adequate intervention and to promote HDT adherence.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Pediatrik (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Pediatrics (hsv//eng)
Nyckelord
- primary gonadal insufficiency; gonadal failure; fertility; hormone therapy; late effects
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas